Randomized Control Study of Nedaplatin or Cisplatin Concomitant with Other Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer

Objective: To observe the short-term efficacy, long-term survival time and adverse responses with nedaplatin(NDP) or cisplatin (DDP) concomitant with other chemotherapy in treating non-small cell lung cancer. Materialsand
Methods: A retrospective, randomized, control study was conducted, in which 619 NSCLC patients in phasesⅢ and Ⅳ who were initially treated and re-treated were randomly divided into an NDP group (n=294) and a DDPgroup (n=325), the latter being regarded as controls. Chemotherapeutic protocols (CP/DP/GP/NP/TP) containingNDP or DDP were given to both groups. Patients in both groups were further divided to evaluate the clinicalefficacies according to initial and re-treatment stage, pathological pattern, type of combined chemotherapeuticprotocols, tumor stage and surgery.
Results: The overall response rate (ORR) and disease control rate (DCR)in the NDP group were 48.6% and 95.2%, significantly higher than in the DDP group at 35.1% and 89.2%,respectively (P<0.01). In NSCLC patients with initial treatment, squamous carcinoma and phase Ⅲ, there weresignificant differences in ORR and DCR between the groups (P<0.05), while ORR was significant in patients withadenocarcinoma, GP/TP and in phase Ⅲa (P<0.05). There was also a significant difference in DCR in patientsin phase Ⅲb (P<0.05). According to the statistical analysis of survival time of all patients and of those in clinicalphase Ⅲ, the NDP group survived significantly longer than the DDP group (P<0.01). The rates of decreasedhemoglobin and increased creatinine, nausea and vomiting in the NDP group were evidently lower than in DDPgroup (P<0.05).
Conclusion: NDP concomitant with other chemotherapy is effective for treating NSCLC, withhigher clinical efficacy than DDP concomitant with chemotherapy, with advantages in prolonging survival timeand reducing toxic and adverse responses.